ABIO Stock - ARCA biopharma Inc.

ABIO Stock Chart

ABIO Profile

ARCA biopharma, Inc. is a clinical-stage biopharmaceutical firm specializing in the development and commercialization of genetically targeted therapies aimed at combating cardiovascular diseases. At the forefront of its pipeline are innovative product candidates like Recombinant Nematode Anticoagulant Protein c2 (rNAPc2) (AB201), currently undergoing Phase IIb clinical trials for potential application in treating COVID-19. Additionally, Gencaro (bucindolol hydrochloride), a beta-adrenergic receptor antagonist tailored through pharmacogenetics, has completed Phase IIb trials for managing atrial fibrillation in chronic heart failure patients.

The company operates through strategic collaborations to enhance its research and development capabilities. Notably, ARCA biopharma, Inc. has forged a partnership with LabCorp to advance genetic testing for the GENETIC-AF clinical trial. Moreover, it maintains a research collaboration with the Colorado Prevention Center, part of the University of Colorado's Academic Research Organization, aimed at further developing and bringing Gencaro to market. Founded in 2004, ARCA biopharma, Inc. is headquartered in Westminster, Colorado, and continues to drive innovation in genetically targeted therapies with the potential to address significant unmet medical needs.

Committed to advancing precision medicine in cardiovascular health, ARCA biopharma, Inc. leverages its deep expertise in genetic therapies to pioneer treatments that offer personalized solutions. By focusing on the genetic aspects of cardiovascular diseases, the company aims to transform patient care with therapies that are tailored to individual genetic profiles, potentially improving efficacy and outcomes while minimizing adverse effects. This patient-centric approach underscores ARCA biopharma, Inc.'s dedication to pioneering the next generation of cardiovascular treatments through rigorous clinical research and strategic partnerships within the biopharmaceutical industry.

ABIO Revenue Chart

ABIO Earnings

Analyst Ratings